Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

247.69
+7.923.30%
Post-market: 247.690.00000.00%19:57 EDT
Volume:1.26M
Turnover:309.17M
Market Cap:16.39B
PE:19.11
High:249.01
Open:239.70
Low:237.23
Close:239.77
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:1.31
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.96
PE(LYR):-56.07

Loading ...

Ascendis Pharma Added to Multiple Russell Indexes

MT Newswires Live
·
Jun 27

Ascendis Pharma Reports Week 104 Approach Trial Data Showing Improved Leg Alignment with Transcon CNP in Achondroplasia

Reuters
·
Jun 26

Movement Alert|Ascendis Pharma Rises 8.3% in Regular Trading, Core Drug Long-Term Clinical Data Impresses as Analysts Reiterate Bullish Stance

Market Focus
·
Jun 26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
Jun 18

Ascendis Pharma sells priority review voucher for $187.5 million cash

Reuters
·
Jun 18

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

TIPRANKS
·
Jun 17

Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)

TIPRANKS
·
Jun 16

Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says

MT Newswires Live
·
Jun 15

Ascendis reports sustained efficacy, safety for TransCon PTH in PaTHway hypoparathyroidism trial at Week 182

Reuters
·
Jun 15

Ascendis Pharma completes Phase 3 PaTHway Trial

TIPRANKS
·
Jun 15

Ascendis says Phase 3 PaTHway trial shows TransCon PTH sustains hypoparathyroidism benefits through Week 182

Reuters
·
Jun 14

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

GlobeNewswire
·
Jun 14

MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk

Dow Jones
·
Jun 13

European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week

MT Newswires Live
·
Jun 12

Ascendis says Phase 2 trial shows TransCon PTH sustains hypoparathyroidism benefits at 5 years

Reuters
·
Jun 12

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

GlobeNewswire
·
Jun 12

Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer

TIPRANKS
·
Jun 09

Ascendis presents final Phase 3 PaTHway results for palopegteriparatide in adult hypoparathyroidism at ENDO 2026

Reuters
·
Jun 09

Ascendis Pharma to present rare endocrine disease data at Endocrine Society ENDO meeting

Reuters
·
Jun 09

Ascendis Pharma CFO Scott Thomas Smith acquires 100 common shares valued at $21,900

Reuters
·
Jun 03